The table below is a review of notable updates that occurred in February 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.

Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Two decades ago, Professor Shao-Cong Sun first discovered the non-canonical NF-κB pathway mediated by NF-κB-inducing kinase (NIK). Since then, more ...

The NF-κB-inducing kinase (NIK), a molecule pivotal for immune system development and function, shows significant yet complex potential as a therapeutic target. The comprehensive review, published by ...

In a cohort study of nearly 16,000 US patients with breast cancer who were prescribed a cyclin-dependent kinase (CDK) 4/6 inhibitor, only 46% underwent liver function testing in the 2 weeks before ...

The impact of neflamapimod on neurofilament light levels will be examined in a study of approximately 35 patients with ALS, facilitated by the EXPERTS-ALS platform, according to a press release from ...

Scientists have uncovered a crucial weakness in the malaria parasite that could open the door to new treatments. Researchers identified a protein called Aurora-related kinase 1 (ARK1) that acts like a ...